Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG039
MIFTS: 61

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 74
Squamous Cell Lung Carcinoma 6 17
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 56

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3907
NCIt 51 C3493
UMLS 74 C0149782
Sources

Summaries for Lung Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Pemetrexed and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Sources

Related Diseases for Lung Squamous Cell Carcinoma

About this section

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.8 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2 adenocarcinoma 31.5 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3 lung cancer susceptibility 3 31.1 AKT1 BRAF EGFR FGFR3 HRAS KRAS
4 adenosquamous carcinoma 30.8 EGFR KRAS PIK3CA TP53
5 breast adenocarcinoma 30.6 AKT1 EGFR KRAS PIK3CA PTEN TP53
6 thymoma 30.6 AKT1 EGFR HRAS TP53
7 small cell carcinoma 30.6 EGFR PTEN TP53
8 intrahepatic cholangiocarcinoma 30.6 EGFR FGFR2 KRAS TP53 TUG1
9 adenoid cystic carcinoma 30.4 AKT1 HRAS KRAS PIK3CA PTEN TP53
10 small cell cancer of the lung 30.3 AKT1 EGFR PIK3CA PTEN TP53 TUG1
11 glioma 30.3 BRAF EGFR PIK3CA PTEN PVT1 TP53
12 melanoma 30.1 BRAF PTEN PVT1 SOX2-OT TP53
13 myelodysplastic syndrome 30.1 HRAS KRAS PTPN11 TERC TP53
14 cholangiocarcinoma 30.0 AKT1 BRAF EGFR KRAS PIK3CA PTEN
15 lung cancer 29.8 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
16 gastric cancer 29.6 AKT1 EGFR FGFR2 KRAS PIK3CA PTEN
17 breast cancer 29.5 AKT1 BRAF EGFR FGFR2 HRAS KRAS
18 lung occult squamous cell carcinoma 11.4
19 lung mixed small cell and squamous cell carcinoma 11.4
20 rare adenocarcinoma of the breast 10.7 AKT1 KRAS PIK3CA TP53
21 breast squamous cell carcinoma 10.7 EGFR PIK3CA TP53
22 estrogen-receptor positive breast cancer 10.7 AKT1 EGFR FGFR2 PIK3CA TP53
23 brain stem glioma 10.7 BRAF EGFR PIK3CA TP53
24 pulmonary blastoma 10.7 EGFR KRAS TP53
25 hyperplastic polyposis syndrome 10.7 BRAF KRAS TP53
26 ovarian cancer 1 10.7 AKT1 KRAS PIK3CA TP53
27 hemifacial hyperplasia 10.7 FGFR2 FGFR3
28 anal squamous cell carcinoma 10.7 AKT1 PIK3CA TP53
29 mature teratoma 10.7 BRAF KRAS TP53
30 brain ependymoma 10.6 EGFR TP53
31 penile cancer 10.6 EGFR PIK3CA TP53
32 lynch syndrome 10.6 BRAF EGFR KRAS TP53
33 pharynx cancer 10.6 AKT1 EGFR TP53
34 nevus of ota 10.6 BRAF TP53
35 ductal carcinoma in situ 10.6 AKT1 EGFR TP53
36 dermatosis papulosa nigra 10.6 FGFR3 PIK3CA
37 bladder disease 10.6 AKT1 FGFR3 TP53
38 plagiocephaly 10.6 FGFR2 FGFR3
39 stomach disease 10.6 AKT1 EGFR TP53
40 adult hepatocellular carcinoma 10.6 PIK3CA TP53
41 lung benign neoplasm 10.6 EGFR HRAS KRAS TP53
42 acneiform dermatitis 10.6 EGFR HRAS KRAS PIK3CA
43 paronychia 10.6 EGFR HRAS KRAS
44 apocrine adenoma 10.6 HRAS KRAS PIK3CA
45 ovary adenocarcinoma 10.6 HRAS KRAS PIK3CA TP53
46 serous cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
47 cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
48 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 KRAS PIK3CA PTEN TP53
49 adenosquamous lung carcinoma 10.6 EGFR FGFR3 HRAS KRAS PIK3CA
50 ovarian clear cell carcinoma 10.6 KRAS PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.77 HRAS KRAS PIK3CA EGFR BRAF
2 Decreased viability GR00106-A-0 10.77 KRAS
3 Decreased viability GR00221-A-1 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
4 Decreased viability GR00221-A-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.77 AKT1 FGFR3 HRAS
6 Decreased viability GR00221-A-4 10.77 AKT1 PIK3CA EGFR BRAF
7 Decreased viability GR00301-A 10.77 KRAS BRAF
8 Decreased viability GR00381-A-1 10.77 KRAS BRAF
9 Decreased viability GR00402-S-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
10 Decreased cell migration GR00055-A-1 9.87 AKT1 BRAF EGFR FGFR3 HRAS KRAS
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR FGFR2 FGFR3 HRAS PTEN PTPN11
12 Increased cell migration GR00055-A-3 9.35 BRAF EGFR HRAS KRAS PIK3CA
13 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR HRAS KRAS NFE2L2 PTEN

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 AKT1 BRAF FGFR2 FGFR3 HRAS KRAS
2 cardiovascular system MP:0005385 10.36 AKT1 BRAF EGFR FGFR2 HRAS KRAS
3 cellular MP:0005384 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
4 growth/size/body region MP:0005378 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5 homeostasis/metabolism MP:0005376 10.34 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6 integument MP:0010771 10.31 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
7 digestive/alimentary MP:0005381 10.3 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
8 embryo MP:0005380 10.29 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
9 immune system MP:0005387 10.29 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
10 adipose tissue MP:0005375 10.28 AKT1 BRAF EGFR FGFR2 NFE2L2 PIK3CA
11 endocrine/exocrine gland MP:0005379 10.28 AKT1 BRAF EGFR FGFR2 HRAS KRAS
12 craniofacial MP:0005382 10.26 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
13 neoplasm MP:0002006 10.26 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
14 nervous system MP:0003631 10.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
15 liver/biliary system MP:0005370 10.16 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
16 muscle MP:0005369 10.15 AKT1 BRAF EGFR FGFR2 KRAS PIK3CA
17 normal MP:0002873 10.14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
18 limbs/digits/tail MP:0005371 10.13 BRAF EGFR FGFR2 FGFR3 KRAS PTEN
19 hearing/vestibular/ear MP:0005377 10.11 BRAF EGFR FGFR2 FGFR3 KRAS PTPN11
20 no phenotypic analysis MP:0003012 10.03 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
21 renal/urinary system MP:0005367 9.97 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
22 reproductive system MP:0005389 9.96 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
23 pigmentation MP:0001186 9.91 BRAF EGFR FGFR2 KRAS PTEN PTPN11
24 respiratory system MP:0005388 9.9 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
25 skeleton MP:0005390 9.73 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
26 vision/eye MP:0005391 9.28 BRAF EGFR FGFR2 FGFR3 KRAS PIK3CA
Sources

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

About this section

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
4
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
7
Nedaplatin Approved, Investigational Phase 4,Phase 3 95734-82-0
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
11
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 60-18-4 6057
12 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Folate Phase 4,Phase 3,Phase 2,Phase 1
16 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
17 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
18
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
19 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
28
Apatinib Phase 4 811803-05-1
29
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 50-18-0, 6055-19-2 2907
31
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
32
afatinib Approved Phase 3,Phase 2 850140-72-6, 439081-18-2 10184653
33
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
34
Vinblastine Approved Phase 3 865-21-4 241903 13342
35
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
36
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
37
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
38
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
39
nivolumab Approved Phase 3,Phase 2 946414-94-4
40
Ipilimumab Approved Phase 3,Phase 2 477202-00-9
41
Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6
42
Durvalumab Approved, Investigational Phase 2, Phase 3,Phase 3 1428935-60-7
43
Palbociclib Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 571190-30-2 5005498 11431660 5330286
44
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
45
Ponatinib Approved, Investigational Phase 2, Phase 3 943319-70-8 24826799
46
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
47
Iniparib Investigational Phase 3 160003-66-7
48
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
49
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
50
Rilotumumab Investigational Phase 2, Phase 3,Phase 3 872514-65-3

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
2 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Apatinib for Advanced Lung Squmamous Carcinoma Not yet recruiting NCT03725423 Phase 4 Apatinib
5 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
6 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Unknown status NCT03150875 Phase 3 Docetaxel
7 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
8 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
9 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
10 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
11 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
12 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
13 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
14 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
15 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
16 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
17 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
18 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
19 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
20 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
21 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
22 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
23 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
24 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
25 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
26 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
27 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
28 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
29 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
30 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
31 A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Recruiting NCT03866993 Phase 3 Paclitaxel;Carboplatin;Placebo
32 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
33 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
34 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
35 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
36 Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
37 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
38 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
39 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
40 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
41 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
42 Electrocautery Ablation for the Prevention of Lung Cancer Not yet recruiting NCT03870152 Phase 2, Phase 3
43 Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer Not yet recruiting NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
44 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
45 A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Not yet recruiting NCT03668496 Phase 3 SHR-1210;The placebo
46 Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated NCT01761747 Phase 2, Phase 3 ponatinib
47 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
48 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
49 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
50 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Sources

Genetic Tests for Lung Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

42
Lung, Brain, Breast, Bone, T Cells, Lymph Node, Thyroid
Sources

Publications for Lung Squamous Cell Carcinoma

About this section

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 462)
# Title Authors Year
1
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab. ( 30859062 )
2019
2
Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas. ( 30246311 )
2019
3
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. ( 30279110 )
2019
4
Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma. ( 30375717 )
2019
5
Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. ( 30389303 )
2019
6
The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma. ( 30456676 )
2019
7
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. ( 30472670 )
2019
8
Primary lung squamous cell carcinoma with gastric metastasis: A case report. ( 30561123 )
2019
9
Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma. ( 30561902 )
2019
10
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. ( 30572178 )
2019
11
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. ( 30642449 )
2019
12
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. ( 30643941 )
2019
13
TBL1XR1 as a potential therapeutic target that promotes epithelial-mesenchymal transition in lung squamous cell carcinoma. ( 30651768 )
2019
14
Increased expression of claudin-12 promotes the metastatic phenotype of human bronchial epithelial cells and is associated with poor prognosis in lung squamous cell carcinoma. ( 30651778 )
2019
15
Knockdown of RNF2 enhances radiosensitivity of lung squamous cell carcinoma cells. ( 30673298 )
2019
16
Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling. ( 30734525 )
2019
17
MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop. ( 30755230 )
2019
18
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. ( 30790149 )
2019
19
Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma. ( 30810839 )
2019
20
Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma. ( 30813343 )
2019
21
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. ( 30815803 )
2019
22
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. ( 30824826 )
2019
23
Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma. ( 30866469 )
2019
24
The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation. ( 30896821 )
2019
25
Expression of miR-486-5p and its significance in lung squamous cell carcinoma. ( 30963622 )
2019
26
Identification of an Exosomal Long Noncoding RNA SOX2-OT in Plasma as a Promising Biomarker for Lung Squamous Cell Carcinoma. ( 30986097 )
2019
27
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma. ( 30987362 )
2019
28
CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma. ( 31019292 )
2019
29
Clinical significance of miRNA‑1 and its potential target gene network in lung squamous cell carcinoma. ( 31059033 )
2019
30
JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. ( 31089135 )
2019
31
Novel methylation-driven genes identified as prognostic indicators for lung squamous cell carcinoma. ( 31105813 )
2019
32
Construction of a transcription factor‑long non‑coding RNA‑microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. ( 30569133 )
2018
33
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. ( 30575913 )
2018
34
The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates. ( 30549039 )
2018
35
UBE2D1 RNA Expression Was an Independent Unfavorable Prognostic Indicator in Lung Adenocarcinoma, but Not in Lung Squamous Cell Carcinoma. ( 30420903 )
2018
36
Discriminating lung adenocarcinoma from lung squamous cell carcinoma using respiration-induced tumor shape changes. ( 30403196 )
2018
37
Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. ( 30128019 )
2018
38
Transcription Factors Contribute to Differential Expression in Cellular Pathways in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. ( 30039492 )
2018
39
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. ( 29756998 )
2018
40
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
41
Lung squamous cell carcinoma associated with hypoparathyroidism with sensorineural deafness and renal dysplasia syndrome: a case report. ( 29593425 )
2018
42
Long non-coding RNAs RP5-821D11.7, APCDD1L-AS1 and RP11-277P12.9 were associated with the prognosis of lung squamous cell carcinoma. ( 29568882 )
2018
43
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese. ( 29578153 )
2018
44
Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma. ( 29616113 )
2018
45
EGFR mutations subset in Chinese lung squamous cell carcinoma patients. ( 29620244 )
2018
46
Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation. ( 29636077 )
2018
47
Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma. ( 29636867 )
2018
48
Epithelial-mesenchymal Transition (EMT) is Correlated with Patient's Prognosis of Lung Squamous Cell Carcinoma. ( 29637533 )
2018
49
Secondary Hypertrophic Osteoarthropathy Associated With Pediatric Primary Lung Squamous Cell Carcinoma. ( 29652703 )
2018
50
Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. ( 29673101 )
2018
Sources

Variations for Lung Squamous Cell Carcinoma

About this section

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 547)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
20 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
21 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
24 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
25 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
26 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
27 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
28 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
29 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
30 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
31 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh37 Chromosome 10, 123279562: 123279562
32 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh38 Chromosome 10, 121520048: 121520048
33 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
34 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
35 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
36 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
37 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
38 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
39 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
40 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
41 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
42 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
44 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
45 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
46 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
47 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
48 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
49 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
50 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 19061)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM7410942 ZSWIM8 lung,NS,carcinoma,adenocarcinoma c.2505G>A p.G835G 10:73799190-73799190 0
2 COSM7411331 ZSWIM5 lung,NS,carcinoma,adenocarcinoma c.2363C>A p.P788H 1:45034398-45034398 0
3 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 0
4 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 2:135200405-135200405 0
5 COSM7411164 ZPBP lung,NS,carcinoma,adenocarcinoma c.966C>G p.I322M 7:49937618-49937618 0
6 COSM7411425 ZPBP lung,NS,carcinoma,adenocarcinoma c.706G>T p.V236F 7:50031092-50031092 0
7 COSM4987559 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 0
8 COSM6490907 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 0
9 COSM6491424 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 0
10 COSM6492724 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 0
11 COSM6492589 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 0
12 COSM6491476 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 0
13 COSM6492792 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 0
14 COSM2768407 ZNF800 lung,NS,carcinoma,adenocarcinoma c.1606C>T p.R536* 7:127373730-127373730 0
15 COSM7411930 ZNF687 lung,NS,carcinoma,adenocarcinoma c.2361C>G p.H787Q 1:151289161-151289161 0
16 COSM7411692 ZNF608 lung,NS,carcinoma,adenocarcinoma c.2023G>A p.V675I 5:124648361-124648361 0
17 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 16:2002647-2002647 0
18 COSM7412390 ZNF536 lung,NS,carcinoma,adenocarcinoma c.2770A>T p.S924C 19:30548389-30548389 0
19 COSM3717849 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 0
20 COSM6492197 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 0
21 COSM1388126 ZNF521 lung,NS,carcinoma,adenocarcinoma c.2365G>A p.G789S 18:25225553-25225553 0
22 COSM6492124 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 0
23 COSM7411528 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1122C>T p.S374S 16:49638030-49638030 0
24 COSM7411524 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1436C>T p.A479V 16:49637716-49637716 0
25 COSM7411526 ZNF423 lung,NS,carcinoma,adenocarcinoma c.1157C>T p.S386F 16:49637995-49637995 0
26 COSM7411530 ZNF423 lung,NS,carcinoma,adenocarcinoma c.634C>A p.H212N 16:49638518-49638518 0
27 COSM3712145 ZNF423 lung,NS,carcinoma,adenocarcinoma c.609C>G p.F203L 16:49638543-49638543 0
28 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 19:53571702-53571702 0
29 COSM7411916 ZNF326 lung,NS,carcinoma,adenocarcinoma c.544G>A p.E182K 1:90007679-90007679 0
30 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 0
31 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 0
32 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 0
33 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 0
34 COSM7412277 ZIC5 lung,NS,carcinoma,adenocarcinoma c.1583G>A p.C528Y 13:99965786-99965786 0
35 COSM6492895 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199T 3:147395943-147395943 0
36 COSM6492512 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 0
37 COSM6492817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33V 3:147410211-147410211 0
38 COSM6492224 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 0
39 COSM6492511 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46A 3:147410250-147410250 0
40 COSM6492896 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 0
41 COSM6491849 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 0
42 COSM6492818 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 0
43 COSM7411445 ZHX1 lung,NS,carcinoma,adenocarcinoma c.1640C>T p.T547M 8:123254307-123254307 0
44 COSM7411890 ZFX lung,NS,carcinoma,adenocarcinoma c.919C>T p.Q307* 23:24207834-24207834 0
45 COSM6491404 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973L 8:76707874-76707874 0
46 COSM6491202 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5661A>G p.K1887K 16:72797021-72797021 0
47 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 0
48 COSM6941511 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.539A>T p.K180M 16:72959607-72959607 0
49 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 0
50 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 0

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma
Sources

Expression for Lung Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.
Sources

Pathways for Lung Squamous Cell Carcinoma

About this section

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.16 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2
Apoptotic Pathways in Synovial Fibroblasts 65
Show member pathways
 14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3
HIV Life Cycle 67
Show member pathways
 13.84 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
4
TGF-Beta Pathway 65
Show member pathways
 13.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5
Developmental Biology 67
Show member pathways
 13.65 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.61 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
7
Akt Signaling 65
Show member pathways
 13.55 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
8
Cytokine Signaling in Immune system 67
Show member pathways
 13.52 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
9
CREB Pathway 65
Show member pathways
 13.45 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
10
PAK Pathway 65
Show member pathways
 13.45 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
11
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.4 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
12
IL-2 Pathway 65
Show member pathways
 13.34 AKT1 BRAF EGFR HRAS KRAS PTEN
13
Phospholipase-C Pathway 65
Show member pathways
 13.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
14
p70S6K Signaling 65
Show member pathways
 13.17 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
15
PI3K-Akt signaling pathway 38
Show member pathways
 13.15 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
16
Human cytomegalovirus infection 38
Show member pathways
 13.12 AKT1 EGFR HRAS KRAS PIK3CA PTEN
17
TNFR1 Pathway 65
Show member pathways
 13.11 AKT1 EGFR HRAS KRAS PIK3CA PTEN
18
Development Angiotensin activation of ERK 23
Show member pathways
 13.08 AKT1 BRAF EGFR HRAS KRAS PIK3CA
19
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.08 AKT1 BRAF EGFR HRAS KRAS PIK3CA
20
Focal Adhesion 1 38
Show member pathways
 13.07 AKT1 BRAF EGFR HRAS KRAS PIK3CA
21
Downstream signaling of activated FGFR2 67
Show member pathways
 13.01 FGFR2 FGFR3 HRAS KRAS PIK3CA PTPN11
22
NFAT and Cardiac Hypertrophy 65
Show member pathways
 13.01 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
23
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.95 AKT1 BRAF HRAS KRAS PIK3CA PTEN
24
Endometrial cancer 38
Show member pathways
 12.95 AKT1 BRAF EGFR FGFR2 HRAS KRAS
25
MAPK signaling pathway 1 38
12.93 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
26
Apoptosis Modulation and Signaling 1
Show member pathways
 12.92 AKT1 HRAS KRAS PIK3CA TP53
27
Development HGF signaling pathway 23
Show member pathways
 12.88 AKT1 BRAF HRAS KRAS PIK3CA PTEN
28
Vascular smooth muscle contraction 38
Show member pathways
 12.86 AKT1 BRAF EGFR HRAS KRAS
29
Ras signaling pathway 38
Show member pathways
 12.85 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
30
4-1BB Pathway 65
Show member pathways
 12.84 AKT1 BRAF EGFR HRAS KRAS TP53
31
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.83 AKT1 EGFR HRAS KRAS PIK3CA PTEN
32
Regulation of actin cytoskeleton 38 1
12.81 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
33
G-AlphaQ Signaling 65
Show member pathways
 12.8 AKT1 BRAF EGFR HRAS KRAS
34
Gastric cancer 38
Show member pathways
 12.78 AKT1 BRAF EGFR FGFR2 HRAS KRAS
35
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.77 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
36
Immune response IL-23 signaling pathway 23
Show member pathways
 12.77 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
37
ErbB signaling pathway 1 38
Show member pathways
 12.74 AKT1 BRAF EGFR HRAS KRAS PIK3CA
38
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.74 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
39
Glioma 38
Show member pathways
 12.73 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
40
Development Dopamine D2 receptor transactivation of EGFR 23
Show member pathways
 12.72 AKT1 EGFR HRAS PIK3CA PTPN11
41
T cell receptor signaling pathway 38
Show member pathways
 12.72 AKT1 HRAS KRAS PIK3CA PTPN11
42
Development EGFR signaling pathway 23
Show member pathways
 12.72 AKT1 BRAF EGFR HRAS KRAS PIK3CA
43
MicroRNAs in cancer 38
12.7 EGFR FGFR3 HRAS KRAS PIK3CA PTEN
44
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.68 AKT1 HRAS PIK3CA PTEN PTPN11
45
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.67 BRAF HRAS KRAS PIK3CA PTPN11
46
Prolactin Signaling Pathway 1 38
Show member pathways
 12.67 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
47
MET promotes cell motility 67
Show member pathways
 12.63 AKT1 HRAS KRAS PIK3CA PTPN11
48
Development FGFR signaling pathway 23
Show member pathways
 12.62 AKT1 FGFR2 FGFR3 HRAS KRAS PIK3CA
49
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.59 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
50
Phospholipase D signaling pathway 38
Show member pathways
 12.59 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
Sources

GO Terms for Lung Squamous Cell Carcinoma

About this section

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
2 positive regulation of protein phosphorylation GO:0001934 9.95 AKT1 EGFR HRAS KRAS
3 peptidyl-tyrosine phosphorylation GO:0018108 9.93 BRAF EGFR FGFR2 FGFR3
4 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 KRAS PIK3CA PTPN11 TP53
5 protein autophosphorylation GO:0046777 9.92 AKT1 EGFR FGFR2 FGFR3
6 negative regulation of neuron apoptotic process GO:0043524 9.89 BRAF HRAS KRAS PIK3CA
7 negative regulation of apoptotic process GO:0043066 9.88 AKT1 BRAF EGFR PTEN TP53
8 liver development GO:0001889 9.87 EGFR KRAS PIK3CA
9 cellular response to mechanical stimulus GO:0071260 9.86 AKT1 EGFR PTPN11
10 fibroblast growth factor receptor signaling pathway GO:0008543 9.86 FGFR2 FGFR3 PTPN11
11 Ras protein signal transduction GO:0007265 9.85 HRAS KRAS TP53
12 positive regulation of epithelial cell proliferation GO:0050679 9.85 EGFR FGFR2 HRAS
13 positive regulation of protein kinase B signaling GO:0051897 9.85 EGFR FGFR2 FGFR3 PIK3CA PTPN11
14 positive regulation of MAP kinase activity GO:0043406 9.84 EGFR HRAS KRAS
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 AKT1 EGFR FGFR2
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 BRAF EGFR PIK3CA
17 T cell costimulation GO:0031295 9.8 AKT1 PIK3CA PTPN11
18 cellular response to drug GO:0035690 9.8 BRAF EGFR NFE2L2 TP53
19 cellular response to epidermal growth factor stimulus GO:0071364 9.78 AKT1 EGFR PTPN11
20 protein kinase B signaling GO:0043491 9.76 AKT1 PIK3CA PTEN
21 positive regulation of MAPK cascade GO:0043410 9.75 FGFR2 FGFR3 HRAS
22 cellular response to nerve growth factor stimulus GO:1990090 9.74 AKT1 BRAF PTEN
23 positive regulation of glucose import GO:0046326 9.72 AKT1 NFE2L2 PTPN11
24 cellular response to hypoxia GO:0071456 9.72 AKT1 NFE2L2 PTEN TERC TP53
25 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.7 AKT1 NFE2L2
26 organ growth GO:0035265 9.7 FGFR2 PTPN11
27 regulation of multicellular organism growth GO:0040014 9.7 FGFR2 PIK3CA PTPN11
28 positive regulation of gene expression GO:0010628 9.7 AKT1 BRAF HRAS KRAS NFE2L2 PTEN
29 anoikis GO:0043276 9.69 AKT1 PIK3CA
30 negative regulation of cell size GO:0045792 9.68 AKT1 PTEN
31 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.68 EGFR TP53
32 positive regulation of phospholipase activity GO:0010518 9.67 FGFR2 FGFR3
33 epidermal growth factor receptor signaling pathway GO:0007173 9.67 AKT1 EGFR PIK3CA PTPN11
34 endochondral bone growth GO:0003416 9.66 FGFR2 FGFR3
35 regulation of axon regeneration GO:0048679 9.66 BRAF PTEN
36 response to isolation stress GO:0035900 9.65 HRAS KRAS
37 cellular response to decreased oxygen levels GO:0036294 9.6 AKT1 PTEN
38 response to UV-A GO:0070141 9.56 AKT1 EGFR
39 MAPK cascade GO:0000165 9.43 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
40 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 BRAF EGFR FGFR2 FGFR3 HRAS PTEN
41 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.1 PIK3CA
42 phosphatidylinositol phosphorylation GO:0046854 8.96 PIK3CA
43 apoptotic process GO:0006915 10.12 AKT1 FGFR2 FGFR3 HRAS PTEN TP53
44 phosphorylation GO:0016310 10.11 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
45 protein phosphorylation GO:0006468 10.09 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
46 cell proliferation GO:0008283 10.02 AKT1 EGFR HRAS PTEN TP53

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 AKT1 BRAF EGFR FGFR2 FGFR3
2 kinase activity GO:0016301 9.85 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
3 protein kinase binding GO:0019901 9.83 AKT1 EGFR PTEN PTPN11 TP53
4 protein tyrosine kinase activity GO:0004713 9.62 BRAF EGFR FGFR2 FGFR3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR2 FGFR3
6 insulin receptor substrate binding GO:0043560 9.48 PIK3CA PTPN11
7 nitric-oxide synthase regulator activity GO:0030235 9.46 AKT1 EGFR
8 nucleotide binding GO:0000166 9.43 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
9 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR2 FGFR3
10 1-phosphatidylinositol-3-kinase activity GO:0016303 8.85 PIK3CA
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.32 PIK3CA
Sources

Sources for Lung Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....